APPENDICES. A systematic review and economic model of the ...

More documents

Recommendations

Info

288 Appendix 12 Core symptoms Educational performance Quality of life Adverse events Total somatic complaints (parents) MPH: 0.85 (1.08) PLA: 0.49 (0.80); F(1,101) = 10.49, p < 0.01 Abbreviated Conners’ Hyperactivity Questionnaire (parents) Means (SD) for NC/ADD/ADD-O populations at 3 weeks: MPH: 0.84 (0.47)/0.99 (0.60)/1.13 (0.60) PLA: 1.29 (0.63)/1.41 (0.60)/1.80 (0.57) MPH > placebo, F(1,101) = 46,72, p < 0.01 Proportion of parents reporting: Poor appetite: MPH: 23.4% PLA: 6.5%; 2 (1, N = 107) = 13.5, p < 0.01 Not reported Valence of weekly comments, parents ratings: Means (SD) for NC/ADD/ADD-O populations at 3 weeks: MPH: 0.24 (0.54)/0.19 (0.56)/0.15 (0.57) PLA: –0.04(0.53)/–0.39(0.38)/–0.29 (0.45) MPH > placebo, F(1,38)=16,09, p < 0.01 Sleep difficulties: MPH: 36.4% PLA: 18.7%; 2 (1, N = 107) = 13.37, p < 0.01 Abbreviated Conners’ Hyperactivity Questionnaire (teachers) Means (SD) for NC/ADD/ADD-O populations at 3 weeks: MPH: 0.43 (0.34)/0.56 (0.42)/0.77 (0.45) PLA: 0.69 (0.43)/1.09 (0.52)/1.80 (0.67) MPH > placebo, F(1,98) = 122.18, p < 0.01 Total counts of negative moods: MPH: 0.64 (0.99) PLA: 1.16 (1.19); F(1,101) = 15.60, p < 0.01 Valence of weekly comments, teacher ratings: Means (SD) for NC/ADD/ADD-O populations at 3 weeks: MPH: 0.27 (0.46)/0.42(0.43)/0.45 (0.32) PLA: 0.09(0.49)/–0.11(0.63)/–0.61 (0.33) MPH > placebo, F(1,38)=52.61, p < 0.01 IOWA Conners’ Scales: inattention/overactivity (parents) Means (SD) for NC/ADD/ADD-O populations at 3 weeks: MPH: 0.90 (0.51)/1.02 (0.73)/1.14 (0.63) PLA: 1.29 (0.55)/1.54 (0.68)/1.81 (0.59) MPH > placebo, F(1,101) = 47.74, p < 0.01 Proportion of parents reporting: Crying: MPH: 19.6% PLA: 37.4%; 2 (1, N = 107) = 9.26, p < 0.01 IOWA Conners’ Scales: inattention/overactivity (teachers) Means (SD) for NC/ADD/ADD-O populations at 3 weeks: MPH: 0.61 (0.48)/0.71 (0.51)/0.87 (0.48) PLA: 0.94 (0.57)/1.44 (0.66)/2.02 (0.69) MPH > placebo, F(1,98)=116.52, p < 0.01 Anger: MPH: 28.0% PLA: 50.5% ; 2 (1, N = 107) = 7.50, p < 0.01 Time on Task Scales (TOTS): hyperactivity (parents) Means (SD) for NC/ADD/ADD-O populations at 3 weeks: MPH: –0.46 (0.37)/–0.44 (0.51)/–0.39 (0.42) PLA: –0.22 (0.41)/–0.11 (0.48)/0.04 (0.41) MPH > placebo, F(1,93)=42.73, p < 0.01 Unhappiness: MPH: 12.1% PLA: 22.4% ; 2 (1, N = 107) = 5.26, p < 0.05 TOTS: hyperactivity (teachers) Means (SD) for NC/ADD/ADD-O populations at 3 weeks: MPH: –1.26 (0.37)/–1.04 (0.43)/–0.89 (0.47) PLA: –0.97 (0.44)/–0.61 (0.45)/–0.14 (0.53) MPH > placebo, F(1,92)=85.57, p < .01 Weight (kg): Baseline: NC: 29.78 (7.75)/ADD: 28.87 (6.42)/ADD-O: 31.34 (9.39) MPH: total group: –0.498 kg PLA: total group: +0.567 kg Total group: F(1,64) = 59.15, p < 0.01 TOTS: attention (parents) Means (SD) for NC/ADD/ADD-O populations at 3 weeks: MPH: 0.11 (0.38)/0.08 (0.49)/0.01 (0.40) PLA: –0.12 (0.34)/–0.09 (0.38)/–0.25 (0.50) MPH > placebo, F(1,93) = 25.73, p < 0.01 continued
Core symptoms Educational performance Quality of life Adverse events TOTS: attention (teachers) Means (SD) for NC/ADD/ADD-O populations at 3 weeks: MPH: 0.48 (0.44)/0.30 (0.49)/0.22 (0.52) PLA: 0.24 (0.38)/–0.08 (0.43)/–0.30 (0.41) MPH > placebo, F(1,92) = 65.00, p < 0.01 Conclusions Authors’ conclusions: The authors concluded that stimulant treatment improved ADD-spectrum children’s behaviour at both home and school not only with regard to inattention and hyperactivity but also aggression/compositionality. MPH increased accuracy on the Sternberg test over levels found in the placebo and baseline sessions, but did not differentially reduce errors to targets Reviewer’s comments: No comments noted © Queen’s Printer and Controller of HMSO 2006. All rights reserved. Health Technology Assessment 2006; Vol. 10: No. 23 289
Page 1 and 2:
Appendices A systematic review and
Page 3 and 4:
Clinical effectiveness information
Page 5 and 6:
Searches for systematic reviews in
Page 7 and 8:
19. methyl phenidate.mp. 20. methyl
Page 9 and 10:
43. attention deficit$.mp. 44. 42 o
Page 11 and 12:
MEDLINE in-process and other non-in
Page 13 and 14:
PsycINFO (1967-July 2004) Searched:
Page 15 and 16:
next aminopropane) or dynaphenyl or
Page 17 and 18:
or ritaline or riphenidate or rital
Page 19:
System for Information on Grey Lite
Page 22 and 23:
166 Appendix 2 S hyperkinetic S imp
Page 24 and 25:
168 Appendix 2 19. (eq5d or eq 5d o
Page 26 and 27:
170 Appendix 2 14. (person trade of
Page 28 and 29:
172 Appendix 3 Reference Reason for
Page 31:
Appendix 4 © Queen’s Printer and
Page 34 and 35:
178 Appendix 5 8. Was the statistic
Page 36 and 37:
180 Appendix 6 Cost-effectiveness R
Page 38 and 39:
182 Appendix 7 Appropriateness of m
Page 40 and 41:
184 Appendix 7 Sensitivity analysis
Page 42 and 43:
186 Appendix 7 Sensitivity analysis
Page 44 and 45:
188 Appendix 8 Probability cost-eff
Page 47 and 48:
Appendix 10 © Queen’s Printer an
Page 49 and 50:
Health state Responder to ATX, no s
Page 51 and 52:
Health state Responder to IR-MPH, R
Page 53 and 54:
Health state Responder to ER-MPH, R
Page 55:
#Baseline shift random effects mode
Page 58 and 59:
202 Appendix 12 Study Intervention
Page 60 and 61:
Page 62 and 63:
206 Appendix 12 Core symptoms Educa
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95: 238 Appendix 12 Core symptoms Educa
Page 114 and 115: 258 Appendix 12 Study Intervention
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222:
366 Appendix 13 Study characteristi
show all

APPENDICES. A systematic review and economic model of the ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?